This suggests that ‘neoantigens’ derived from the BCR-ABL fusion gene may provoke specific immune responses, making CML cells a potential target for the immune system [12]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.